This article was originally published in The Tan Sheet
In the article "Prevacid Initial Launch Efforts To Focus On Switching Prescription Users," (1"The Tan Sheet" May 18, 2009, p. 3), we inadvertently implied that Novartis intends to market Prevacid 24HR to current users of prescription Prevacid for gastroesophageal reflux disease. We should have said the firm aims to market Prevacid 24HR to the subset of its Rx patients that suffer from frequent heartburn. "The Tan Sheet" regrets the misstatement
You may also be interested in...
Novartis plans to prioritize converting patients currently treated with prescription Prevacid when the proton pump inhibitor becomes available over-the-counter, rather than winning over Prilosec OTC users, a Novartis executive said
Salus Haus has expanded its popular Floradix range with an immunity boosting liquid supplement and a children's verison of its flagship Floradix Liquid product.
GSK revealed price increases in the US, Europe and China as it posted Q3 sales up high single-digits, with gains in key categories such as pain relief and vitamins, minerals and supplements.